RAPID MICRO BIOSYSTEMS, INC. (RPID) stock intrinsic value fair value estimate & owner earnings analysis

Rapid Micro Biosystems makes Growth Direct, an automated system that pharmaceutical and cell-and-gene-therapy manufacturers use to test their products for microbial contamination. It has placed 190 systems and sold about 9 million consumable test cartridges. Customers include 75% of the top twenty pharmaceutical companies. Once a system is installed and validated, it produces recurring consumable and service revenue. MilliporeSigma has a co-exclusive distribution agreement and has committed to buy a minimum number of systems over the first two years of that agreement. This is a real product with real customers, but it has never made money, and that is what drives our valuation. What the numbers show. Revenue grew from $17.1M in 2022 to $22.5M in 2023, $28.1M in 2024 and $33.6M in 2025. The company first reported positive gross margins in the second half of 2024, but that was only 3.1% for all of 2025, and the fourth quarter of 2025 slipped back to a negative 3%. Operating cash flow has been negative every year: $(58.5)M in 2022, $(45.1)M in 2023, $(44.2)M in 2024 and $(31.1)M in 2025. Stock-based pay of about $4M a year is a real cost, and we deduct it. Growth spending on equipment has been small. After those adjustments, the business consumed about $41M of owner earnings in 2025, or about $0.92 per share. That is an improvement from about $1.51 per share of losses in 2022, but it is still a loss. About $6M of the 2025 cash improvement came from collecting receivables and working down inventory, which does not repeat, and we have removed it. Net loss barely changed, at $47.1M versus $46.9M the year before. Trend. Through the first half of 2026, revenue rose about 11% to $16.1M. Operating cash burn rose to $27.8M, from $18.8M in the same period of 2025. The share count is also rising, from about 44.7M to 48.3M weighted diluted shares, so existing owners are being diluted to fund the losses. Funding position. At year-end 2025 the company held $38.3M of cash and investments. It owes $20M under a secured term loan to Trinity Capital, due September 2030, which is secured by substantially all assets. A further $20M is available only if commercial and operational milestones are met. At the recent burn rate, the year-end cash covers roughly a year or less. The loan agreement treats a delisting from Nasdaq as a default. The company received a minimum-bid-price warning in the past and has regained compliance. We do not treat delisting as a present concern, but it is a live risk. Management states a goal of positive cash flow without new financing, but says plainly that it is not assured and depends on more revenue, better gross margins and cost cuts. Our cases. We include only drivers we can name and evidence today. Growth is credited only when it is secured or a proven, repeatable process. Bear case ($0.00 per share): Burn stays near $40M a year, the remaining cash and the milestone-based loan tranches are used up around 2027, and the lender, which holds the first claim on all assets, ends up ahead of shareholders. Shareholders receive nothing, which is the floor for a share of stock. Base case ($0.00 per share): Revenue keeps growing and gross margins stay thin. The losses are financed by new shares and debt, so whatever value the business creates goes to the people funding it. We cannot name a contracted or long-proven driver that turns owner earnings positive. Revenue growth has lasted only two to three years, has not yet cut the loss, and slowed to 11% in early 2026. Margin expansion and management's cash-flow goal are not credited, since they depend on things that have not yet happened. Nothing evidenced produces positive earnings, so this case is worth $0. Bull case ($0.00 per share): The strongest case we can support is that the lenders' milestone tranches are met and the MilliporeSigma minimum purchases are delivered. That funds a longer runway, but it does not produce positive owner earnings within a defensible horizon. Even if the improvement seen from 2022 to 2025 continued, about $3M to $8M a year, the cumulative cash consumed before breakeven exceeds the cash and debt capacity on hand. It would take new equity, and we do not credit the value of unearned profits after that. So even this case is worth $0 today. Upside exists only if the company reaches positive owner earnings, and it is not something we can price from evidence yet. What would make this wrong. If gross margin moved well into positive territory on a sustained basis while operating costs stayed flat, owner earnings could turn positive much sooner than the past trend suggests. We saw a hint of this with the positive gross margins of late 2024, but the fourth quarter of 2025 showed a reversal, and the first half of 2026 shows higher burn, not lower. We will revisit the valuation once several quarters of improving cash flow are in hand. Until then no margin-of-safety price applies. Cash at the end of June 2026 could not be established from the filings available to us, so the runway estimate rests on year-end 2025 cash.